Mendus
Mendus to participate in several investor and industry conferences in January
Press Release
Stockholm, Sweden, January 7, 2025
Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:
43rd Annual J.P. Morgan Healthcare Conference
San Francisco, USA, January 13-16, 2025
Mendus management team will be in San Francisco for business and investor meetings during the J.P, Morgan conference
14th Annual LifeSci Partners Corporate Access Event
San Francisco, USA, January 13-15, 2025
Mendus will take part in the LifeSci Corporate Access investor event
H.C. Wainwright & Co. during JPM 2025
San Francisco, USA, January 13-16, 2025
Mendus will attend the H.C. Wainwright conference and events during JPM
Redeye Theme: Fight Cancer
Stockholm, Sweden, January 22, 2025
Mendus CEO Erik Manting will present the company and take part in a discussion panel. For more information, please see
https://www.redeye.se/events/1052608/redeye-theme-fight-cancer-3?tab=abouttheevent
Datum | 2025-01-07, kl 08:00 |
Källa | MFN |